Your browser doesn't support javascript.
loading
Large-Scale Characterization of Drug Responses of Clinically Relevant Proteins in Cancer Cell Lines.
Zhao, Wei; Li, Jun; Chen, Mei-Ju M; Luo, Yikai; Ju, Zhenlin; Nesser, Nicole K; Johnson-Camacho, Katie; Boniface, Christopher T; Lawrence, Yancey; Pande, Nupur T; Davies, Michael A; Herlyn, Meenhard; Muranen, Taru; Zervantonakis, Ioannis K; von Euw, Erika; Schultz, Andre; Kumar, Shwetha V; Korkut, Anil; Spellman, Paul T; Akbani, Rehan; Slamon, Dennis J; Gray, Joe W; Brugge, Joan S; Lu, Yiling; Mills, Gordon B; Liang, Han.
Afiliação
  • Zhao W; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Li J; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Chen MM; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Luo Y; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Graduate Program in Quantitative and Computational Biosciences, Baylor College of Medicine, Houston, TX 77030, USA.
  • Ju Z; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Nesser NK; Department of Molecular and Medical Genetics, Oregon Health & Science University, Portland, OR 97201, USA.
  • Johnson-Camacho K; Department of Molecular and Medical Genetics, Oregon Health & Science University, Portland, OR 97201, USA.
  • Boniface CT; Department of Molecular and Medical Genetics, Oregon Health & Science University, Portland, OR 97201, USA.
  • Lawrence Y; Department of Molecular and Medical Genetics, Oregon Health & Science University, Portland, OR 97201, USA.
  • Pande NT; Department of Molecular and Medical Genetics, Oregon Health & Science University, Portland, OR 97201, USA.
  • Davies MA; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Herlyn M; Molecular and Cellular Oncogenesis Program, Wistar Institute, Philadelphia, PA 19104, USA.
  • Muranen T; Department of Cell Biology, Ludwig Center at Harvard, Harvard Medical School, Boston, MA 02115, USA.
  • Zervantonakis IK; Department of Cell Biology, Ludwig Center at Harvard, Harvard Medical School, Boston, MA 02115, USA; Department of Bioengineering, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA 15219, USA.
  • von Euw E; Division of Hematology-Oncology, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA.
  • Schultz A; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Kumar SV; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Korkut A; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Spellman PT; Department of Molecular and Medical Genetics, Oregon Health & Science University, Portland, OR 97201, USA.
  • Akbani R; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Slamon DJ; Division of Hematology-Oncology, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA.
  • Gray JW; Center for Spatial Systems Biomedicine, Department of Biomedical Engineering, Oregon Health & Science University, Portland, OR 97201, USA.
  • Brugge JS; Department of Cell Biology, Ludwig Center at Harvard, Harvard Medical School, Boston, MA 02115, USA.
  • Lu Y; Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Mills GB; Knight Cancer Institute and Cell, Developmental and Cancer Biology, Oregon Health & Science University, Portland, OR 97201, USA. Electronic address: gmills@ohsu.org.
  • Liang H; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Graduate Program in Quantitative and Computational Biosciences,
Cancer Cell ; 38(6): 829-843.e4, 2020 12 14.
Article em En | MEDLINE | ID: mdl-33157050
ABSTRACT
Perturbation biology is a powerful approach to modeling quantitative cellular behaviors and understanding detailed disease mechanisms. However, large-scale protein response resources of cancer cell lines to perturbations are not available, resulting in a critical knowledge gap. Here we generated and compiled perturbed expression profiles of ∼210 clinically relevant proteins in >12,000 cancer cell line samples in response to ∼170 drug compounds using reverse-phase protein arrays. We show that integrating perturbed protein response signals provides mechanistic insights into drug resistance, increases the predictive power for drug sensitivity, and helps identify effective drug combinations. We build a systematic map of "protein-drug" connectivity and develop a user-friendly data portal for community use. Our study provides a rich resource to investigate the behaviors of cancer cells and the dependencies of treatment responses, thereby enabling a broad range of biomedical applications.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteômica / Mapas de Interação de Proteínas / Neoplasias / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Cancer Cell Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteômica / Mapas de Interação de Proteínas / Neoplasias / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Cancer Cell Ano de publicação: 2020 Tipo de documento: Article